{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:50:27Z","timestamp":1790801427762,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-IBHU-0002"],"award-info":[{"award-number":["ANR-18-IBHU-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116160","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:02:14Z","timestamp":1764432134000},"page":"116160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5566-9740","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Debiais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-3554","authenticated-orcid":false,"given":"Anthony","family":"Tarabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Blanchet-Deverly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine M.","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Megherbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Diebakate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-6196","authenticated-orcid":false,"given":"Cristina","family":"Smolenschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Val\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6591-2213","authenticated-orcid":false,"given":"Thomas","family":"Pudlarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Cristina","family":"Fuerea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-4663","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Boil\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2025.116160_bib2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"JCO"},{"issue":"19","key":"10.1016\/j.ejca.2025.116160_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.116160_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"10409","key":"10.1016\/j.ejca.2025.116160_bib5","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2025.116160_bib6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2730","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2025.116160_bib7","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.ejca.2025.116160_bib8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116160_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"0","key":"10.1016\/j.ejca.2025.116160_bib10","article-title":"Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or s-1, irinotecan, and oxaliplatin versus nab-paclitaxel + gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): a randomized, open-label, phase II\/III ial","volume":"0","author":"Ohba","year":"2025","journal-title":"JCO"},{"issue":"17_","key":"10.1016\/j.ejca.2025.116160_bib11","article-title":"Early results of the PASS-01 trial: pancreatic adenocarcinoma signature stratification for treatment-01","volume":"42","author":"Knox","year":"2024","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.ejca.2025.116160_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pan.2024.06.004","article-title":"The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer","volume":"24","author":"Levine","year":"2024","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.ejca.2025.116160_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-023-11377-1","article-title":"Treatment sequences and prognostic\/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe","volume":"23","author":"Taieb","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.116160_bib14","doi-asserted-by":"crossref","unstructured":"Ryan D.P., Hong T.S., Bardeesy N. The New England Journal of Medicine. Massachusetts Medical Society; 2014 [cited 2025 Aug 31]. Pancreatic Adenocarcinoma. Available from: https:\/\/www-nejm-org.ezproxy.u-paris.fr\/doi\/\u3008full\/10.1056\/NEJMra1404198\u3009.","DOI":"10.1056\/NEJMra1404198"},{"issue":"4","key":"10.1016\/j.ejca.2025.116160_bib15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116160_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejca.2025.116160_bib17","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C utation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2025.116160_bib18","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1838","article-title":"652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)","volume":"34","author":"Arbour","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.116160_bib19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.22.02668","article-title":"Prediction of adjuvant gemcitabine sensitivity in resectable pancreatic adenocarcinoma using the gemPred RNA signature: an ancillary study of the PRODIGE-24\/CCTG PA6 clinical trial","volume":"42","author":"Nicolle","year":"2024","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.ejca.2025.116160_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2024.06.010","article-title":"Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma","volume":"35","author":"Fraunhoffer","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116160_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12885-024-12016-z","article-title":"Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study","volume":"24","author":"Gueiderikh","year":"2024","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.116160_bib22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ijc.31751","article-title":"Results from the prospective German TPK clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma","volume":"144","author":"Hegewisch-Becker","year":"2019","journal-title":"Int J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:04:34Z","timestamp":1773857074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"alternative-id":["S0959804925010469"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116160","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116160"}}